|
Serum albumin measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
A genome-wide assessment of variability in human serum metabolism.
|
23281178 |
2013 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Further gain-of-function study showed that ZBTB28 functions as a tumor suppressor inhibiting carcinoma cell growth <i>in vitro</i> and <i>in vivo</i>, through inducing cell cycle arrest and apoptosis of tumor cells.
|
31754389 |
2019 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Although it was recently demonstrated that reduced expression of BCL6B is associated with tumor stage and lymph node metastasis in CRC, little is known on whether BCL6B contributes to CRC development, or the related underlying mechanism.
|
29393377 |
2018 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
BCL6B is a potential tumor suppressor in human gastric cancer, but the regulation and mechanism of BCL6B in human hepatocellular carcinogenesis remain unclear.
|
25909168 |
2015 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
BCL6B functions as a tumor suppressor that inhibits HCC metastases in vitro and in vivo.
|
25218345 |
2014 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We previously showed that BCL6B acts as a tumor suppressor in gastric cancer and up to 66% gastric cancer patients have promoter hypermethylation in tumor tissues.
|
24191714 |
2013 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
BCL6B plays a pivotal role as a potential tumour suppressor in GC.
|
21917650 |
2012 |
|
Malignant neoplasm of stomach
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Finally, significant negative correlations were detected between the mRNA levels of BCL6B and inflammatory cytokines in human GC tissues; patients harbouring BCL6B-negetive and severe-inflammation GC tumours were found to exhibit the shortest survival time.
|
31288844 |
2019 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
However, the functions and mechanism of ZBTB28 in carcinogenesis remain unclear.
|
31754389 |
2019 |
|
Carcinogenesis
|
0.040 |
PosttranslationalModification
|
phenotype |
BEFREE |
Bcl6b was gradually downregulated by its own promoter hypermethylation in parallel to an increasing inflammatory response during the progression of BaP-induced gastric carcinogenesis in mice.
|
31288844 |
2019 |
|
Stomach Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Finally, significant negative correlations were detected between the mRNA levels of BCL6B and inflammatory cytokines in human GC tissues; patients harbouring BCL6B-negetive and severe-inflammation GC tumours were found to exhibit the shortest survival time.
|
31288844 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
B‑cell CLL/lymphoma 6 member B (BCL6B), a BCL6‑homologous gene, has been reported to be a tumor suppressor that is silenced in a variety of human cancers, including colorectal cancer (CRC).
|
29393377 |
2018 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
BCL6B is a potential tumor suppressor in human gastric cancer, but the regulation and mechanism of BCL6B in human hepatocellular carcinogenesis remain unclear.
|
25909168 |
2015 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
In addition, transcriptomic microarray analysis was performed to explore the mechanisms in which BCL6B confers protection from tumorigenesis.
|
25970780 |
2015 |
|
Malignant Neoplasms
|
0.040 |
PosttranslationalModification
|
group |
BEFREE |
The methylation of B-cell CLL/lymphoma 6 member B (BCL6B) DNA promoter was detected in several malignancies.
|
25008234 |
2014 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
B cell CLL/lymphoma 6 member B (BCL6B) is a novel tumor suppressor silenced in human cancer.
|
25218345 |
2014 |
|
Malignant neoplasm of stomach
|
0.040 |
PosttranslationalModification
|
disease |
BEFREE |
Here, we quantitatively detect the methylated status of CpG sites of BCL6B DNA promoter of 459 patients with gastric cancer (GC) by using bisulfite gene sequencing.
|
25008234 |
2014 |
|
Stomach Carcinoma
|
0.040 |
PosttranslationalModification
|
disease |
BEFREE |
Here, we quantitatively detect the methylated status of CpG sites of BCL6B DNA promoter of 459 patients with gastric cancer (GC) by using bisulfite gene sequencing.
|
25008234 |
2014 |
|
Malignant neoplasm of stomach
|
0.040 |
Biomarker
|
disease |
BEFREE |
BCL6B methylation may serve as a novel potential non-invasive plasma biomarker for the detection of gastric cancer.
|
24191714 |
2013 |
|
Stomach Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
BCL6B methylation may serve as a novel potential non-invasive plasma biomarker for the detection of gastric cancer.
|
24191714 |
2013 |
|
Malignant Neoplasms
|
0.040 |
PosttranslationalModification
|
group |
BEFREE |
Using genome-wide promoter methylation assay, B cell CLL/lymphoma 6 member B (BCL6B) was found to be preferentially methylated in cancer.
|
21917650 |
2012 |
|
Malignant neoplasm of stomach
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Re-expression of BCL6B in GC cell lines inhibited colony formation, suppressed cell viability, induced apoptosis and restrained the tumorigenecity in nude mice.
|
21917650 |
2012 |
|
Stomach Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Re-expression of BCL6B in GC cell lines inhibited colony formation, suppressed cell viability, induced apoptosis and restrained the tumorigenecity in nude mice.
|
21917650 |
2012 |
|
Liver carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Moreover, a positive correlation between BCL6B expression and hepatic cirrhosis was found in an analysis of HCC clinicopathological characteristics.
|
25970780 |
2015 |
|
Liver carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Loss of BCL6B expression was found in 19 of completely methylated HCC cell lines.
|
25909168 |
2015 |